Log In
BCIQ
Print this Print this
 

gacyclidine (OTO-311)

  Manage Alerts
Collapse Summary General Information
Company Otonomy Inc.
DescriptionSustained-exposure formulation of gacyclidine, an NMDA receptor antagonist
Molecular Target NMDA receptor
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationTinnitus
Indication DetailsTreat tinnitus
Regulatory Designation
PartnerIpsen Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/06/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today